Chancroid, formerly a major cause of the genital
ulcer disease syndrome, remains an important cofactor in both the transmission and acquisition of HIV-1
infection. Those countries with the greatest burden of HIV also have some of the highest prevalence rates of
chancroid worldwide. The diagnosis of
chancroid, caused by the fastidious bacterium Haemophilus ducreyi, is both expensive and difficult in many resource-poor areas. These areas of the world use syndromic management to treat genital
ulcers and such an approach has proven effective in reducing rates of bacterial genital
ulcer diseases. There are currently inexpensive and effective single-dose
therapies available to treat
chancroid. Single-dose regimens, given at first presentation, improve compliance and reduce the risk of
sexually transmitted infections. Bacterial resistance to several
antimicrobial agents has increased over the years and remains a continued threat to effective antimicrobial
therapy. Follow-up of cases, and partner notification and treatment is carried out to limit
reinfection and onward transmission of
chancroid. Patients with coexistent HIV may be particularly at risk of failing single-dose
therapy and should therefore be reviewed wherever possible.